Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18706031 | 0.90 | KDM4E (0.39) | MAPTKDM4ENSD2ALDH1A1NOTUM | |
| SCHEMBL15032720 | 0.77 | MAPT (0.56) | MAPTKDM4ENSD2ALDH1A1NOTUM | |
| SCHEMBL789412 | 0.75 | ALDH1A1 (0.43) | ALDH1A1NOTUM | |
| SCHEMBL12538927 | 0.74 | CYP2A6 (0.39) | MAPT | |
| SCHEMBL17673592 | 0.74 | PDE1C (0.38) | NOTUMKDM4CBRD4CREBBP | |
| SCHEMBL2780359 | 0.73 | ALDH1A1 (0.35) | MAPTKDM4EALDH1A1 | |
| SCHEMBL14484415 | 0.73 | CYP1A2 (0.42) | KDM4E | |
| SCHEMBL517925 | 0.73 | CA1 (0.50) | KDM4EALDH1A1 | |
| SCHEMBL16734315 | 0.72 | MEN1 (0.36) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL1128777 | 0.72 | ESR1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-12516044-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4137489-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-109890819-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-3472167-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3390361-B1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORP (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210363137-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-11-25 | — | — | US | disclosed |
| US-20210317139-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-10-14 | — | — | US | disclosed |
| EP-3472167-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3390361-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | Incyte Corporation (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180273519-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-09-27 | — | — | US | disclosed |
| WO-2017222976-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-12-21 | — | — | US | disclosed |
| WO-2017106634-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORPORATION (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-06-22 | — | — | US | disclosed |
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
| WO-2011008931-A2 | ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010068863-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317139-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4685/4885KDM4E 3719/4885NSD2 1929/4885 |
| US-20180273519-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4651/4885KDM4E 3674/4885NSD2 1985/4885 |
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MAPT 4685/4885KDM4E 3719/4885NSD2 1929/4885 |
| US-20210363137-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4651/4885KDM4E 3674/4885NSD2 1985/4885 |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | MAPT 4853/4885KDM4E 4417/4885NSD2 3076/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | MAPT 4839/4885KDM4E 4270/4885NSD2 2169/4885 |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4651/4885KDM4E 3674/4885NSD2 1985/4885 |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4685/4885KDM4E 3719/4885NSD2 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.